ClinicalTrials.gg
Sign In
CompletedNCT02716051WISLONUpdated Jul 5, 2019

Wholebody MRI In Lung Cancer StagiNg

An interventional study of MRI and PET in Lung Cancer, sponsored by University Hospital, Limoges. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-05.

Sponsored by University Hospital, Limoges · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Magnetic Resonnace Imaging (MRI) and Positron Emission Tomography (PET) can be both used in detection of nodes in patients with cell lung cancer (NSCLC).

However, the cardiorespiratory synchronization in the MRI, allowing acquisition of synchronous images with breathing and heart movements should increase the sensitivity of detection of pathologic mediastinal lymph nodes.

Given its high sensitivity, whole-body MRI with diffusion could possibly be at least as informative as PET, while being less expensive, not radiant.

The purpose of this study is to evaluate the performance of whole-body MRI with diffusion with cardiorespiratory synchronization, on the detection of mediastinal nodes (which are known to be less well detected by MRI) compared to PET.

02

Conditions studied

  • Lung Cancer

Browse trials for

03

In context

Lung Neoplasms

7,333 studies on the registry are indexed under Lung Neoplasms; 1,554 are open to participants now.

This study's enrollment of 36 is below the median of 60 across 5,345 interventional studies indexed under Lung Neoplasms.

Browse Lung Neoplasms studies →

Lead sponsor

University Hospital, Limoges is the lead sponsor of 262 studies on the registry; 37 are open to participants now.

Browse University Hospital, Limoges studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • At least 18 years,
  • Neoplasia bronchopulmonary (SCLC and NSCLC) newly diagnosed,
  • Patient potentially eligible for curative treatment, but no no treatment started,
  • Patients for whom a PET scan and MRI are planned

Non Inclusion Criteria:

  • claustrophobia,
  • Implantable Medical Device
  • not compatible pacemaker type or heart valve, metal splinters eye)
  • Pregnant or lactating women,
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    MRI

    Wholebody MRI with cardio-pulmonary synchronization At day 1 , at the afternoon, patient will undergo an MRI analysis.

    Device: MRI

  • Active comparator
    PET

    At day 1 , in the morning, patient will undergo an PET analysis

    Device: PET

Interventions

  • DeviceMRI

    Whole body MRI with cardiac and pulmonary synchronization

  • DevicePET
06

What researchers measure

Primary outcomes

  1. Th consistency of the locations of mediastinal lesions

    Node localization according to MRI and PET scan measurements on the same day

    Time frame: Day 1

07

Study locations

1 site
  • CHU Limoges
    Limoges, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Dec 2018, 33 months.

Of 774 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's 33 months is below that.

Counting every sponsor, half of 818 studies reached it within 39 months; a quarter within 17 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2016
First posted
Mar 23, 2016
StartActual
Mar 2016
Primary completionActual
Dec 2018
CompletionActual
Jun 2019
Last update
Jul 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02716051
Lead sponsor
University Hospital, Limoges
Responsible party
Sponsor
First posted
Mar 23, 2016
Start date
Mar 2016
Primary completion
Dec 2018
Completion
Jun 2019
Last update
Jul 5, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lung Neoplasms →

Other studies from this sponsor

University Hospital, Limoges →

Start the discussion